Avalo Therapeutics Files Prospectus For Offering Up To 128,189 Common Shares On Behalf Of Selling Shareholders
Avalo Therapeutics Inc AVTX
$18.25
▼ -5.88%
($-1.14)
🔥 High Short Interest
📅 Earnings This Week
Open
$19.50
Prev Close
$19.39
Day Range
$18.24 – $19.73
52W Range
$6.57 – $24.27
Market Cap
$965.48M
Beta
0.75
EPS (TTM)
$-6.04
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2015-11-13 |
| Shares Out. | 52,900,000 |
| Website | avalotx.com/ ↗ |
| Phone | 14105228707 |
| Employees | 33 |
| Net Income | -$19.6M |
| Total Assets | $99.9M |
| Total Liabilities | $31.6M |
| Equity | $68.3M |
About Avalo Therapeutics Inc
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
Avalo Therapeutics Inc is a publicly traded company under the ticker symbol AVTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
20 analysts (2026-07-01)